{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:37:54Z","timestamp":1790523474004,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,12,12]],"date-time":"2002-12-12T00:00:00Z","timestamp":1039651200000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2002,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the safety and efficacy of MRA, a recombinant human anti\u2013interleukin\u20106 (anti\u2013IL\u20106) receptor monoclonal antibody of the IgG1 subclass that inhibits the function of IL\u20106, in patients with established rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A randomized, double\u2010blind, placebo\u2010controlled, dose\u2010escalation trial was conducted in 45 patients with active RA, as defined by the American College of Rheumatology (ACR) revised criteria. Patients were sequentially allocated to receive a single intravenous dose of either 0.1, 1, 5, or 10 mg\/kg of MRA or placebo. The primary efficacy end point was meeting the ACR 20% response criteria at week 2 after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Demographic features were similar between treatment groups. At week 2, a significant treatment difference was observed between the 5 mg\/kg of MRA and placebo, with 5 patients (55.6%) in the MRA cohort and none in the placebo cohort achieving ACR 20% improvement. There was no statistically significant difference in the ACR 20% response between the other 3 MRA cohorts and placebo at week 2. The mean disease activity score at week 2 in those who received 5 mg\/kg and 10 mg\/kg of MRA was 4.8 and 4.7 (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001 and\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001 by analysis of variance), respectively. These mean scores were statistically significantly lower than those in the 0.1\u2010 and 1\u2010mg\/kg MRA and the placebo cohorts (6.4, 6.2, and 7.0, respectively). The erythrocyte sedimentation rate and C\u2010reactive protein values fell significantly in the 5\u2010 and 10\u2010mg\/kg MRA cohorts and normalized 2 weeks after treatment. Seventeen patients (5, 4, 6, 2, and 0 patients in the placebo, 0.1\u2010, 1\u2010, 5\u2010, and 10\u2010mg\/kg MRA cohorts, respectively) required corticosteroid or disease\u2010modifying antirheumatic drug treatment because of active disease before study end. They were regarded as nonresponders from the time they received these treatments. Diarrhea was the most common adverse event, occurring in 8% of patients. Seven patients (15.6%) reported a severe adverse event (3, 1, 2, and 2 patients in the placebo, 0.1\u2010, 1\u2010, and 10\u2010mg\/kg MRA cohorts). There were no serious adverse events that were thought to be related to the study drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first randomized controlled trial showing that inhibition of IL\u20106 significantly improved the signs and symptoms of RA and normalized the acute\u2010phase reactants. Further research with multiple dosing is necessary to define the most appropriate therapeutic regimen of MRA in RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.10623","type":"journal-article","created":{"date-parts":[[2002,12,16]],"date-time":"2002-12-16T08:50:56Z","timestamp":1040028656000},"page":"3143-3150","source":"Crossref","is-referenced-by-count":423,"title":["Therapeutic benefit of blocking interleukin\u20106 activity with an anti\u2013interleukin\u20106 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double\u2010blind, placebo\u2010controlled, dose\u2010escalation trial"],"prefix":"10.1002","volume":"46","author":[{"given":"E. H. S.","family":"Choy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Garrood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Farrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Hazleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yoshizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. S.","family":"Panayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,12,12]]},"reference":[{"issue":"2","key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.59","article-title":"Long\u2010term outcome in rheumatoid arthritis","volume":"34","author":"Pincus T","year":"1995","journal-title":"Br J Rheumatol"},{"key":"e_1_2_6_3_2","first-page":"912","volume-title":"Textbook of rheumatology","author":"Harris ED","year":"1993"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0896-8411(92)90027-N"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113921"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830181122"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310614"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.3109\/03009748809098809"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.797"},{"key":"e_1_2_6_10_2","first-page":"22","article-title":"Serial estimation of interleukin\u20106 as a measure of systemic disease in rheumatoid arthritis","volume":"19","author":"Dasgupta B","year":"1992","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110113"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1042\/bst020138s"},{"key":"e_1_2_6_13_2","first-page":"259","article-title":"Treatment of severe rheumatoid arthritis by anti\u2010interleukin\u20106 monoclonal antibody","volume":"20","author":"Wendling D","year":"1993","journal-title":"J Rheumatol"},{"issue":"9","key":"e_1_2_6_14_2","first-page":"S133","article-title":"Anti\u2010IL\u20106 receptor antibody suppresses the onset of collagen arthritis in monkeys","volume":"40","author":"Masahiko M","year":"1997","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_6_16_2","first-page":"86","article-title":"World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials","volume":"41","author":"Boers M","year":"1994","journal-title":"J Rheumatol"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"issue":"9","key":"e_1_2_6_19_2","first-page":"S84","article-title":"Safety and efficacy of repetitive treatment with humanized anti\u2010interleukin\u20106 receptor antibody (MRA) in rheumatoid arthritis (RA)","volume":"44","author":"Nishimoto N","year":"2001","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103223441207"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-2-199801150-00009"},{"key":"e_1_2_6_25_2","first-page":"2582","article-title":"A multicenter cross sectional study on bone mineral density in rheumatoid arthritis","volume":"7","author":"Sinigaglia L","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.54.4.329"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/31.5.293"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.10623","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.10623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T10:11:44Z","timestamp":1700734304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.10623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["10.1002\/art.10623"],"URL":"https:\/\/doi.org\/10.1002\/art.10623","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12]]}}}